Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-014557
Filing Date
2025-02-18
Accepted
2025-02-18 06:19:26
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12234
2 JOINT FILING AGREEMENT ea023134201ex1_lixte.htm EX-1 3272
  Complete submission text file 0001213900-25-014557.txt   17266
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Subject) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-81115 | Film No.: 25632585
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 245 PALM TRAIL DELRAY BEACH FL 33483
Business Address 245 PALM TRAIL DELRAY BEACH FL 33483 8475629030
INTRACOASTAL CAPITAL, LLC (Filed by) CIK: 0001646799 (see all company filings)

EIN.: 320460881 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G